Jerome Dejulia
Internal Medicine · Cassville, PANPI 1841270220
Payments from drug & device makers
Across 330 payments — averaging $12.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$869
- AstraZeneca$594
- Novo Nordisk$537
- Lilly USA, LLC$368
- Johnson & Johnson$291
- Boehringer Ingelheim$276
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,77099%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 90 | $869 |
| AstraZeneca | 20 | $594 |
| Novo Nordisk | 46 | $537 |
| Lilly USA, LLC | 30 | $368 |
| Johnson & Johnson | 23 | $291 |
| Boehringer Ingelheim | 20 | $276 |
| Sanofi-aventis U.S. LLC | 17 | $212 |
| Pfizer | 31 | $205 |
| Amarin Pharma, Inc. | 9 | $155 |
| AbbVie(2 entities) | 5 | $83 |
| Merck | 6 | $82 |
| Amgen | 5 | $73 |
| Astellas Pharma US Inc | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $68 |
| Novartis | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Shire North American Group Inc | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
How this compares
$4,157 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $90,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $78,617 |
| EliquisApixaban | 45 | $39,480 |
| TrulicityDulaglutide | 34 | $36,960 |
| JardianceEmpagliflozin | 28 | $24,058 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $23,358 |
| MounjaroTirzepatide | 17 | $18,666 |
| Repatha SyringeEvolocumab | 14 | $11,324 |
| MyrbetriqMirabegron | 12 | $8,868 |
| JanuviaSitagliptin Phosphate | 11 | $6,046 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,149 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $4,700 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,644 |
| Atorvastatin Calcium | 241 | $3,655 |
| Omeprazole | 199 | $2,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $537 | $90,71379 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $869 | $88,410137 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $368 | $55,62651 claims |
| PfizerEliquis | $205 | $39,48045 claims |
| Boehringer IngelheimJardiance | $276 | $24,05828 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $8,86812 claims |
| MerckJanuvia | $82 | $6,04611 claims |
| AbbVieSynthroid | $83 | $1,06623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Cassville
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.